Metabolic Disease & Stroke: Hyperglycemia/Hypoglycemia: Follow-up

References

1. Aslan Y, Dinc H. MR findings of neonatal hypoglycemia [letter; comment]. AJNR Am J Neuroradiol. May 1997;18(5):994-6. [Medline].

2. Bath PM. Optimising homeostasis. Br Med Bull. 2000;56(2):422-35. [Medline].

3. Berkovic SF, Bladin PF, Darby DG. Metabolic disorders presenting as stroke. Med J Aust. Mar 31 1984;140(7):421-4. [Medline].

4. Browning RG, Olson DW, Stueven HA. 50% dextrose: antidote or toxin?. Ann Emerg Med. Jun 1990;19(6):683-7. [Medline].

5. Bruno A, Biller J, Adams HP Jr. Acute blood glucose level and outcome from ischemic stroke. Trial of ORG 10172 in Acute Stroke Treatment (TOAST) Investigators. Neurology. Jan 15 1999;52(2):280-4. [Medline].

6. Calles-Escandon J, Garcia-Rubi E, Mirza S. Type 2 diabetes: one disease, multiple cardiovascular risk factors. Coron Artery Dis. 1999;10(1):23-30. [Medline].

7. Capes SE, Hunt D, Malmberg K, et al. Stress hyperglycemia and prognosis of stroke in nondiabetic and diabetic patients: a systematic overview. Stroke. Oct 2001;32(10):2426-32. [Medline].

8. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. May 21 2003;289(19):2560-72. [Medline].

9. DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med. Sep 30 1993;329(14):977-86. [Medline].

10. Demchuk AM, Morgenstern LB, Krieger DW. Serum glucose level and diabetes predict tissue plasminogen activator- related intracerebral hemorrhage in acute ischemic stroke. Stroke. Jan 1999;30(1):34-9. [Medline].

11. Garg R, Chaudhuri A, Munschauer F, Dandona P. Hyperglycemia, insulin, and acute ischemic stroke: a mechanistic justification for a trial of insulin infusion therapy. Stroke. Jan 2006;37(1):267-73. [Medline].

12. Gold AE, Marshall SM. Cortical blindness and cerebral infarction associated with severe hypoglycemia. Diabetes Care. Sep 1996;19(9):1001-3. [Medline].

13. Gorelick PB, Sacco RL, Smith DB. Prevention of a first stroke: a review of guidelines and a multidisciplinary consensus statement from the National Stroke Association. JAMA. Mar 24-31 1999;281(12):1112-20. [Medline].

14. Kawai N, Keep RF, Betz AL. Hyperglycemia and the vascular effects of cerebral ischemia. Stroke. Jan 1997;28(1):149-54. [Medline].

15. Lawson ML, Gerstein HC, Tsui E. Effect of intensive therapy on early macrovascular disease in young individuals with type 1 diabetes. A systematic review and meta-analysis. Diabetes Care. Mar 1999;22 Suppl 2:B35-9. [Medline].

16. Lukovits TG, Mazzone TM, Gorelick TM. Diabetes mellitus and cerebrovascular disease. Neuroepidemiology. 1999;18(1):1-14. [Medline].

17. Parsons MW, Barber PA, Desmond PM, et al. Acute hyperglycemia adversely affects stroke outcome: a magnetic resonance imaging and spectroscopy study. Ann Neurol. Jul 2002;52(1):20-8. [Medline].

18. Quast MJ, Wei J, Huang NC, et al. Perfusion deficit parallels exacerbation of cerebral ischemia/reperfusion injury in hyperglycemic rats. J Cereb Blood Flow Metab. May 1997;17(5):553-9. [Medline].

19. Richardson ML, Kinard RE, Gray MB. CT of generalized gray matter infarction due to hypoglycemia. AJNR Am J Neuroradiol. Jul-Aug 1981;2(4):366-7. [Medline].

20. Robins SJ, Collins D, Wittes JT, et al. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. JAMA. Mar 28 2001;285(12):1585-91. [Medline].

21. Shotliff K, Prasad A, Millard P. Hypoglycaemia masquerading as a stroke [letter]. Postgrad Med J. Oct 1992;68(804):843. [Medline].

22. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. Dec 14 1995;333(24):1581-7. [Medline].

23. The NINDS t-PA stroke study group. Generalized efficacy of t-PA for acute stroke. Subgroup analysis of the NINDS t-PA Stroke Trial. Stroke. Nov 1997;28(11):2119-25. [Medline].

24. [Best Evidence] Van den Berghe G, Schoonheydt K, Becx P, et al. Insulin therapy protects the central and peripheral nervous system of intensive care patients. Neurology. Apr 26 2005;64(8):1348-53. [Medline].

25. Van den Berghe G, Wilmer A, Hermans G, et al. Intensive insulin therapy in the medical ICU. N Engl J Med. Feb 2 2006;354(5):449-61. [Medline].

26. van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in the critically ill patients. N Engl J Med. Nov 8 2001;345(19):1359-67. [Medline].

27. Wallis WE, Donaldson I, Scott RS. Hypoglycemia masquerading as cerebrovascular disease (hypoglycemic hemiplegia). Ann Neurol. Oct 1985;18(4):510-2. [Medline].

28. Young GB, Roper AH, Bolton CF. Metabolic encephalopathies. Coma and impaired consciousness: a clinical perspective. 1998;Chapter 13:333-8.

29. Zweifler RM. Management of acute stroke. South Med J. Apr 2003;96:380-5. [Medline].

Further Reading

Keywords

hyperglycemia, hypoglycemia, acute stroke, diabetes, diabetes mellitus, thrombolytic therapy, anticoagulation therapy, transient ischemic attack, TIA, recombinant tissue-type plasminogen activator, rtPA, metabolic disease and stroke

Contributor Information and Disclosures

Author

Pitchaiah Mandava, MD, PhD, Assistant Professor, Department of Neurology, Baylor College of Medicine; Consulting Staff, Department of Neurology, Michael E DeBakey Veterans Affairs Medical Center
Pitchaiah Mandava, MD, PhD is a member of the following medical societies: American Academy of Neurology, Sigma Xi, and Stroke Council of the American Heart Association
Disclosure: Nothing to disclose.

Coauthor(s)

Thomas A Kent, MD, Professor, Department of Neurology, Baylor College of Medicine; Neurology Care Line Executive, Michael E DeBakey Veterans Affairs Medical Center
Thomas A Kent, MD is a member of the following medical societies: American Academy of Neurology, American Neurological Association, New York Academy of Sciences, Royal Society of Medicine, Sigma Xi, and Stroke Council of the American Heart Association
Disclosure: Nothing to disclose.

Medical Editor

Richard M Zweifler, MD, Professor, Director of Stroke Center, Director of Neurosonology Lab, Director of Vascular Neurology Fellowship, Director of Medical Student Education, Department of Neurology, University of South Alabama
Richard M Zweifler, MD is a member of the following medical societies: American Academy of Neurology, American Heart Association, American Medical Association, American Society of Neuroimaging, American Stroke Association, Medical Association of the State of Alabama, National Stroke Association, Royal Society of Medicine, Society of Neurosurgical Anesthesia and Critical Care, and Stroke Council of the American Heart Association
Disclosure: Nothing to disclose.

Pharmacy Editor

Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: Nothing to disclose.

Managing Editor

Howard S Kirshner, MD, Professor of Neurology, Psychiatry and Hearing and Speech Sciences, Vice Chairman, Department of Neurology, Vanderbilt University School of Medicine; Director, Vanderbilt Stroke Center; Program Director, Stroke Service, Vanderbilt Stallworth Rehabilitation Hospital; Consulting Staff, Department of Neurology, Nashville Veterans Affairs Medical Center
Howard S Kirshner, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Neurology, American Heart Association, American Medical Association, American Neurological Association, American Society of Neurorehabilitation, National Stroke Association, Phi Beta Kappa, and Tennessee Medical Association
Disclosure: Boehringer Ingelheim Honoraria Speaking and teaching; BMS/Sanofi Honoraria Speaking and teaching; Pfizer Honoraria Speaking and teaching; Novartis Consulting fee Review panel membership

CME Editor

Selim R Benbadis, MD, Professor, Director of Comprehensive Epilepsy Program, Departments of Neurology and Neurosurgery, University of South Florida School of Medicine, Tampa General Hospital
Selim R Benbadis, MD is a member of the following medical societies: American Academy of Neurology, American Academy of Sleep Medicine, American Clinical Neurophysiology Society, American Epilepsy Society, and American Medical Association
Disclosure: Nothing to disclose.

Chief Editor

Helmi L Lutsep, MD, Associate Professor, Department of Neurology, Oregon Health and Science University; Associate Director, Oregon Stroke Center
Helmi L Lutsep, MD is a member of the following medical societies: American Academy of Neurology and American Stroke Association
Disclosure: Co-Axia Consulting fee Review panel membership; Talecris Consulting fee Review panel membership; AGA Medical Consulting fee Review panel membership; Boehringer Ingelheim Honoraria Speaking and teaching; Boston Scientific Honoraria Speaking and teaching